Literature DB >> 9482801

Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo.

D T Weldon1, S D Rogers, J R Ghilardi, M P Finke, J P Cleary, E O'Hare, W P Esler, J E Maggio, P W Mantyh.   

Abstract

To determine the stability of beta-amyloid peptide (Abeta) and the glial and neuronal changes induced by Abeta in the CNS in vivo, we made single injections of fibrillar Abeta (fAbeta), soluble Abeta (sAbeta), or vehicle into the rat striatum. Injected fAbeta is stable in vivo for at least 30 d after injection, whereas sAbeta is primarily cleared within 1 d. After injection of fAbeta, microglia phagocytize fAbeta aggregates, whereas nearby astrocytes form a virtual wall between fAbeta-containing microglia and the surrounding neuropil. Similar glial changes are not observed after sAbeta injection. Microglia and astrocytes near the injected fAbeta show a significant increase in inducible nitric oxide synthase (iNOS) expression compared with that seen with sAbeta or vehicle injection. Injection of fAbeta but not sAbeta or vehicle induces a significant loss of parvalbumin- and neuronal nitric oxide synthase-immunoreactive neurons, whereas the number of calbindin-immunoreactive neurons remains unchanged. These data demonstrate that fAbeta is remarkably stable in the CNS in vivo and suggest that fAbeta neurotoxicity is mediated in large part by factors released from activated microglia and astrocytes, as opposed to direct interaction between Abeta fibrils and neurons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482801      PMCID: PMC6792921     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  83 in total

1.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.

Authors:  B A Yankner; L K Duffy; D A Kirschner
Journal:  Science       Date:  1990-10-12       Impact factor: 47.728

2.  Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures.

Authors:  C J Pike; A J Walencewicz; C G Glabe; C W Cotman
Journal:  Eur J Pharmacol       Date:  1991-08-14       Impact factor: 4.432

Review 3.  Alzheimer's disease: a central role for amyloid.

Authors:  D J Selkoe
Journal:  J Neuropathol Exp Neurol       Date:  1994-09       Impact factor: 3.685

4.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.

Authors:  A Goate; M C Chartier-Harlin; M Mullan; J Brown; F Crawford; L Fidani; L Giuffra; A Haynes; N Irving; L James
Journal:  Nature       Date:  1991-02-21       Impact factor: 49.962

5.  Selective loss of calbindin D28K-immunoreactive neurons in the cortical layer II in brains of Alzheimer's disease: a morphometric study.

Authors:  E Nishiyama; J Ohwada; N Iwamoto; H Arai
Journal:  Neurosci Lett       Date:  1993-12-12       Impact factor: 3.046

6.  Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.

Authors:  D A Sanan; K H Weisgraber; S J Russell; R W Mahley; D Huang; A Saunders; D Schmechel; T Wisniewski; B Frangione; A D Roses
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

7.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity.

Authors:  M P Mattson; B Cheng; D Davis; K Bryant; I Lieberburg; R E Rydel
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

8.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

Authors:  K C Evans; E P Berger; C G Cho; K H Weisgraber; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Beta amyloid is neurotoxic in hippocampal slice cultures.

Authors:  M R Harrigan; D D Kunkel; L B Nguyen; A T Malouf
Journal:  Neurobiol Aging       Date:  1995 Sep-Oct       Impact factor: 4.673

10.  Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity.

Authors:  B J Cummings; C W Cotman
Journal:  Lancet       Date:  1995-12-09       Impact factor: 79.321

View more
  95 in total

1.  Microglia in Alzheimer's disease and transgenic models. How close the fit?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Decreased rhythmic GABAergic septal activity and memory-associated theta oscillations after hippocampal amyloid-beta pathology in the rat.

Authors:  Vincent Villette; Frédérique Poindessous-Jazat; Axelle Simon; Clément Léna; Elodie Roullot; Brice Bellessort; Jacques Epelbaum; Patrick Dutar; Aline Stéphan
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 3.  Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases.

Authors:  Tomohiro Nakamura; Dong-Hyung Cho; Stuart A Lipton
Journal:  Exp Neurol       Date:  2012-07-05       Impact factor: 5.330

4.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

5.  Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2.

Authors:  T V Petrova; K T Akama; L J Van Eldik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

6.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

7.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

8.  Ocular changes in TgF344-AD rat model of Alzheimer's disease.

Authors:  Yuchun Tsai; Bin Lu; Alexander V Ljubimov; Sergey Girman; Fred N Ross-Cisneros; Alfredo A Sadun; Clive N Svendsen; Robert M Cohen; Shaomei Wang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

9.  Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer's disease.

Authors:  Ai-Guo Xuan; Xue-Bing Pan; Peng Wei; Wei-Dong Ji; Wen-Juan Zhang; Ji-Hong Liu; Le-Peng Hong; Wen-Liang Chen; Da-Hong Long
Journal:  Mol Neurobiol       Date:  2014-05-23       Impact factor: 5.590

Review 10.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.